Septal myectomy after previous septal artery ablation in hypertrophic cardiomyopathy

Andrew W ElBardissi1, Jospeh A Dearani, Rick A Nishimura

  • 1Division of Cardiovascular Surgery, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.

Mayo Clinic Proceedings
|December 7, 2007
PubMed

Insights

Septal artery ablation failure in hypertrophic cardiomyopathy patients necessitates septal myectomy, which effectively reduces left ventricular outflow tract gradient and improves symptoms, despite increased risks. This procedure offers significant relief for patients unresponsive to ablation.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Cardiac Surgery

Background:

  • Septal artery ablation is a treatment for hypertrophic cardiomyopathy (HCM).
  • Some patients do not benefit from septal artery ablation and require further intervention.
  • Septal myectomy is a surgical option for HCM, but its efficacy after failed ablation is less understood.

Purpose of the Study:

  • To review the institutional experience with septal myectomy after failed septal artery ablation.
  • To identify reasons for septal artery ablation failure.
  • To evaluate the outcomes of septal myectomy in patients with prior ablation.

Main Methods:

  • Retrospective analysis of 16 patients who underwent septal myectomy after septal artery ablation.
  • Comparison with a control group of 120 patients who underwent septal artery ablation.
  • Review of angiograms, echocardiograms, and clinical data to assess ablation failure and myectomy outcomes.

Main Results:

  • Septal myectomy significantly reduced left ventricular outflow tract (LVOT) gradient and mitral regurgitation post-procedure.
  • All surviving patients experienced symptom improvement at follow-up.
  • Patients undergoing myectomy after ablation had higher operative mortality and morbidity compared to controls.

Conclusions:

  • Septal myectomy is effective in improving LVOT gradient and relieving symptoms in patients with failed septal artery ablation.
  • However, this patient group faces a higher risk of complications and mortality.
  • Careful patient selection and management are crucial for septal myectomy after ablation.
Abstract

Related Concept Videos

Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...